Two brain sensors could catch drowsiness before it turns deadly

NCT ID NCT05453643

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 ยท Last updated Sep 21, 2026

Summary

Researchers are testing whether two EEG sensors can reliably measure sleepiness caused by sleep loss or disrupted sleep cycles. About 40 healthy adults with no sleep complaints take part in lab sessions that include extended wakefulness, interrupted sleep, simulated driving, and attention tasks every four hours. The goal is to build methods that predict drowsiness-related attention lapses and lower the risk of accidents tied to secondary hypersomnolence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sleep deprivation patterns and EEG-based drowsiness monitoring
What this could lead to
If it works, this could give drivers and workplaces a simple two-sensor way to spot dangerous drowsiness before it causes an accident.
What could go wrong
The study is small and tests drowsiness in a lab, not real driving, so the sensor readings may not translate to real-world crash prevention. EEG signals also vary between people, which can make automated detection unreliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Mar 2023

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI between 18 and 27, * With a score on the PHQ-4 scale less than or equal to 2 for scores A (Anxiety) and D (Depression), * Subjects with no complaints of excessive daytime sleepiness (total ESS score \<11), * Non-professional drivers, * Subjects who have held their driving license for at least one year, * Subjects affiliated to a social security scheme, * Subjects able to understand the study, * Subjects available to come to the 3 visits required by the study, * Free, informed and written consent signed Exclusion Criteria: * Pathologies that can induce excessive daytime sleepiness: untreated narcolepsy or idiopathic hypersomnia, untreated restless legs syndrome, untreated periodic leg movement syndrome, * Chronic insomnia disorder, * Excessive alcohol consumption (\> 2 glasses per day) during the last 6 months, * Excessive consumption of coffee, tea or cola-type caffeinated beverages (\> 5 cups/day), * Severe pathologies involving the vital prognosis in the short term, * Uncontrolled endocrine pathologies (dysthyroidism, diabetes), * All progressive cardiac pathologies, treated or untreated, * All progressive neurological conditions treated or not (brain tumor, epilepsy, migraine, stroke, sclerosis, myoclonus, chorea, neuropathy, muscular dystrophies, myotonic dystrophy, etc.), * Substance dependence, * Shift workers or night workers who have performed on-call or on-call duty in the last 72 hours, * Patients taking psychotropic drugs (antidepressants, antihistamines), * Long-term treatment with benzodiazepines and z-drugs, * Patients on cardiotropic, * Deprived of liberty by a judicial or administrative decision, * Pregnant or breastfeeding woman, * Subject under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sleep deprivation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sleep Deprivation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU bordeaux

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.